Related Experiment Video
Updated: Jun 11, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Smokeless tobacco: challenges, products and, cessation
K Vendrell Rankin1, Daniel L Jones, Elain Benton
1Baylor Tobacco Treatment Services, Department of Public Health Sciences, Baylor College of Dentistry TAMHSC, Dallas, Texas, USA.
New smokeless tobacco (ST) products bypass smoke-free laws and complicate cessation. Despite varying ST contents, pharmacotherapy shows promise for quitting, with dentists playing a key role.
Area of Science:
- Oral Health
- Tobacco Control
- Public Health
Background:
- Tobacco companies are aggressively marketing new oral smokeless tobacco (ST) products.
- These products are designed for oral dissolution and swallowing, circumventing smoke-free policies.
- ST use poses significant health risks beyond oral cancer and complicates cessation efforts.
Purpose of the Study:
- To review the health risks associated with new smokeless tobacco products.
- To examine the challenges in smokeless tobacco cessation pharmacotherapy.
- To highlight the role of dental professionals in motivating ST cessation.
Main Methods:
- Literature review on smokeless tobacco products and cessation strategies.
- Analysis of health risks and carcinogen content in ST.
- Evaluation of pharmacotherapy effectiveness for ST cessation.
Main Results:
- New ST products effectively bypass smoke-free policies and promote dual use with cigarettes.
- ST products contain nicotine and carcinogens, posing widespread health risks.
- Variability in ST product composition hinders standardized pharmacotherapy, though research suggests effectiveness.
Conclusions:
- Smokeless tobacco cessation is challenging due to product diversity and regulatory loopholes.
- Pharmacotherapy can be effective for ST cessation, but guidelines are lacking.
- Dentists are crucial motivators for patients to quit smokeless tobacco use.
More Related Videos
10:44Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
09:30A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
Published on: January 18, 2018
Related Concept Videos
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Drug Dependence
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...